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Abstract
Background: Commissioning innovative health technologies is typically complex and multi-faceted. Drawing on
the negotiated order perspective, we explore the process by which commissioning organisations make their
decisions to commission innovative health technologies. The empirical backdrop to this discussion is provided by a
case study exploring the commissioning considerations for a new photoplethysmography-based diagnostic
technology for peripheral arterial disease in primary care in the UK.
Methods: The research involved an empirical case study of four Clinical Commissioning Groups (CCGs) involved in
the commissioning of services in primary and secondary care. Semi-structured in-depth interviews (16 in total) and
two focus groups (a total of eight people participated, four in each group) were conducted with key individuals
involved in commissioning services in the NHS including (i) senior NHS clinical leaders and directors (ii)
commissioners and health care managers across CCGs and (iii) local general practitioners.
Results: Commissioning of a new diagnostic technology for peripheral arterial disease in primary care involves high
levels of protracted negotiations over funding between providers and commissioners, alliance building, conflict
resolution and compromise of objectives where the outcomes of change are highly contingent upon interventions
made across different care settings. Our evidence illustrates how reconfigurations of inter-organisational relations,
and of clinical and related work practices required for the successful implementation of a new technology could
become the major challenge in commissioning negotiations.
Conclusions: Innovative health technologies such as the diagnostic technology for peripheral arterial disease are
commissioned in care pathways where the value of such technology is realised by those delivering care to patients.
The detail of how care pathways are commissioned is complex and involves high degrees of uncertainty
concerning such issues as prioritisation decisions, patient benefits, clinical buy-in, value for money and unintended
consequences. Recent developments in the new care models and integrated care systems (ICSs) in the UK offer a
unique opportunity for the successful commissioning arrangements of innovative health technologies in primary
care such as the new diagnostic technology for peripheral arterial disease.
Keywords: Commissioning, Decision-making, Diagnostics, Innovative health technologies, Primary care, Peripheral
arterial disease, United Kingdom
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Background
Despite the growth of studies examining the process of
implementing technologies in healthcare, there has been
limited research on the decision making processes (i.e.
pre-implementation assessment criteria) surrounding the
commissioning of innovative health technologies in
practice [1]. This oversight is somewhat paradoxical
given current policy pressures towards ‘evidence-based
policy-making’ and ‘evidence-based decision-making’ [2]
and the push for adoption of new technology in health-
care. In particular, understanding how decisions are
made by those commissioning healthcare services still
remains unclear.
Over the past decade, the role of commissioning has
become increasingly important to the health system in
England. Commissioning is a decision making process
by which public services are planned, contracted and
monitored to meet population needs. It involves much
more than procuring services and managing transac-
tional issues with activities ranging from the health
needs assessment for a population, through the clinically
based design of patient pathways, to service specification
and contract negotiation or procurement, with continu-
ous quality assessment [3]. The Health and Social Care
Act (HSCA) 2012 which is the legislative basis for the
current NHS structure led to significant changes in the
organisation of the NHS. It brought in a new commis-
sioning environment in which competition, patient
choice and integration of services each play a more
prominent role. Most of the National Health Service
(NHS) commissioning budget is now managed by clin-
ical commissioning groups (CCGs). At a national level,
NHS England is responsible for the commissioning of
services outside the remit of clinical commissioning
groups, in particular specialized services, primary care
and some public health services [4].
In the context of health services research this lack of
attention could be related to the timing and the meth-
odological difficulties (i.e. negotiating access) researchers
may have in capturing the decision making process for
commissioning innovative health technologies. Typically,
empirical studies have been carried out retrospectively at
some chronological distance from the initial commis-
sioning negotiations, the outcome of which underpins
the identification, assessment and decision making cri-
teria surrounding the implementation of care pathways.
Indeed, in most cases the process of commissioning is
only briefly introduced prior to the implementation
phase where it becomes subject to economic forms of
analysis (i.e. commissioning as a technical or operational
process) where the assumption is that commissioning is
the outcome of formal planning and economic assess-
ment procedures which seek to maximise the value of
resources and improve the health and wellbeing of the
community [5]. More recent sociological approaches
view commissioning as a relational process, driven by
the micro-politics of the organisational setting, compet-
ing agendas, interests, priorities, demands and personal
inclinations to build a persuasive, compelling case [5–7].
A distinguishing feature of these approaches is their
emphasis on the social dynamics and power relations
within which commissioning decisions become enacted
over time. In so doing, these sociological explanations
highlight the various contingencies and uncertainties
surrounding decision-making as a complex process of
conflict, negotiation and alignment [8]. Drawing upon
Strauss’ negotiated order perspective [9, 10], we view
commissioning decision-making as an outcome of con-
tingent negotiations among different social actors who
collectively negotiate the formal and informal ‘rules’ that
shape the delivery of healthcare services. The negotiated
order perspective provides a means to understand the
processes involved in commissioning decision-making
by exploring the social structures and conditions that
shape those processes. In line with such ideas we argue
that commissioning should be understood as an emer-
gent and contingent process in that it is constantly de-
fined and redefined across multiple contexts. As such,
both the technical and organizational dimensions of
commissioning decision making tend to be characterized
by high degrees of uncertainty concerning such issues as
prioritisation decisions, patient benefits, clinical buy-in,
value for money and unintended consequences [11].
This paper explores the process by which commission-
ing organisations make their decisions to commission
innovative health technologies. The empirical backdrop
to this discussion is provided by a case study exploring
commissioning considerations for a new and fast diag-
nostic technology (utilizing multi-site photoplethysmo-
graphy; MPPG) [12–14] for peripheral arterial disease in
primary care, a diagnostic innovation for the treatment
of vascular disease. Peripheral arterial disease (PAD)
affects approximately 20% of patients aged ≥60 years
[15] and is a lens to view additional cardiovascular path-
ology including myocardial infarction and stroke risk
[16]. Currently, there is a high degree of variation related
to the availability and delivery of PAD services across
primary and secondary care. The new MPPG-based
PAD device uses an automated portable diagnostic tech-
nology developed by a North East England device devel-
opment team (NIHR i4i funded project: II-C1–0412-20,
003) which aims to improve on current diagnostic accur-
acy, reduce test speed and is simple to use by a range of
health care practitioners in primary care. It is aimed to
be used at the first patient contact and to identify
patients that need either reassurance, primary preven-
tion of cardiovascular risk factors or onward referral for
specialist intervention [15] and ultimately to reduce
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unnecessary referrals [17]. This is particularly important
when current guidance is a default referral strategy to a
vascular surgeon if there is doubt about the diagnosis
[18, 19]. At present, the ankle brachial pressure index
(ABPI) test (ratio of the ankle to brachial systolic blood
pressure as usually measured by sphygmomanometer
and hand-held Doppler ultrasound probe) is widely used
and by a diverse range of practitioners (in the commu-
nity and hospital setting) to screen asymptomatic pa-
tients, diagnose patients with clinical symptoms, and to
monitor patients who have had radiological or surgical
intervention [20]. However, as many as one-third of
patients at risk are currently going undetected [21] when
primary prevention measures could have a significant
impact upon future morbidity and mortality. In the con-
text of primary care, as many as one in five patients in
the general practice setting may have peripheral arterial
disease [22] and the question of testing for such disease
comes into sharp focus particularly when new technol-
ogy such as the MPPG-based PAD device may make this
a real possibility and also serves as a window on general
cardiovascular health. Here, we explore the process by
which commissioners make their decisions to commis-
sion a pathway for the new diagnostic technology in
primary care practice.
Methods
Semi-structured in-depth interviews (16 in total; see
Table 1) and two focus groups (a total of eight people
participated, four in each group) were conducted between
July 2015 and September 2016 across four localities in one
geographical region in England. The semi-structured in-
terviews were conducted with commissioners working
across four clinical commissioning groups in a mixed
urban and rural area. Two focus groups conducted with
one CCG in a rural area, aimed to capitalise on the inter-
actions between a group of senior commissioners provid-
ing a balance with the semi-structured interviews [23]. A
topic guide, informed by previous studies on commission-
ing [24] was developed to structure the interviews and
focus group, the same guide used for both, to explore the
decision making process of commissioning by partici-
pants. The topic guide was designed to encourage partici-
pants to reflect on successful and unsuccessful practices
for commissioning in the context of innovative health
technology and to cover perceptions of (i) the organisa-
tional structures, processes, relationships, barriers and
facilitators related to commissioning and (ii) the relative
influence of policy drivers, relationships with providers
and external influences.
Participants were purposively selected according to
their role and involvement in commissioning services in
primary and secondary care, on the recommendation of
members of an external research advisory steering group
set up for the purpose of the study. Participants included
(i) senior NHS clinical leaders and directors (ii) commis-
sioners and health care managers across CCGs and (iii)
local general practitioners (GPs). The steering group was
formed to provide specialist advice around primary care
commissioning, review interim findings and assist with
the evaluation of the outputs of the project. The steering
group met every 6 month and included (i) an NHS
Table 1 List of participants
Organisation Number of interviews Interviewees




CCG Site 2 4 Senior Manager/GP ×2
Senior Commissioning Manager × 2
CCG Site 3 4 Clinical Director
Senior Commissioning Manager × 3
Clinical Network 1 Senior Manager
NHS 2 GPs
Focus groups
CCG Site 4 Senior Clinical Officer
Clinical Director
Senior Commissioning Manager ×4
Locality Manager ×2
Total 24
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clinical director and (ii) two senior commissioning man-
agers/GPs.
Potential interviewees were sent an email invitation
which outlined the aims and objectives of the study.
Those agreeing to participate were also invited to rec-
ommend additional candidates for interview. Individuals
who agreed to participate in the study were provided
with information sheets in advance, and consent forms
were signed prior to the start of the interviews. All inter-
views and focus groups were digitally recorded, anon-
ymized and transcribed in full. Interviews were typically
around 60 min in length and conducted on an individual,
face-to-face basis. Each focus group was approximately
90 min long and conducted at the workplace of the par-
ticipants. Two researchers (GM and SW) conducted the
fieldwork. Many interviewees had multiple roles both as
commissioners and providers of primary and secondary
care services and therefore opinions expressed often rep-
resented their experiences from both areas of practice.
Data analysis
Drawing upon an interpretative approach interviews
were analysed inductively, without the aid of a software
programme. Data transcripts were read through to fa-
miliarise with content and were then subjected to the-
matic analysis [25]. Core categories and themes were
identified for each participant and then compared within
each case. Two members of the research team (GM and
SW) undertook the analysis of interview data and emer-
ging categories. The themes were then reviewed and
discussed within the wider project team meetings with
any discrepancies resolved through this process. The
results were also validated with the steering group which
was formed to provide guidance on the research design
and review interim findings. In this paper, all partici-
pants have been anonymised.
Ethics
A positive ethical opinion was obtained from Newcastle
University Faculty of Medical Sciences Ethics Committee
(ref: 00831/2015). NHS Research Ethics approval was
not required for this study as per the Health Research
Authority guidance.
Results
Analysis of the data generated five broad themes relating
to commissioning a pathway for the new type of PAD
diagnostic technology in primary care practice: 1) man-
aging competing priorities 2) valuing evidence 3) assessing
value for money 4) cross-organisational collaboration 5)
and negotiating commissioning pathways. These themes
represent some of the factors shaping the decision-making
processes surrounding the commissioning of the new
diagnostic technology in primary care rather than linear
criteria to determine such decisions. Indeed, the overall
context in which the complex process of commissioning
and how decision-making takes place remains both uncer-
tain and fluid.
Managing competing priorities
Participants highlighted the important role of priority
setting in commissioning a pathway for the new diagnos-
tic technology in primary care practice. With limited
resources, improving the quality and outcomes of ser-
vices for the local population was considered to be a key
factor shaping commissioning decision making.
It needs to link with our priorities because we have a
finite amount of resources … We can't afford to fund
things that are doing well, to fund it even further
(Senior Commissioning Manager, CCG Site 3)
It was acknowledged that the drive for change may
come from multiple sources and informed by both in-
ternal (expert advice from GPs/clinicians) and external
(clinical guidelines) factors.
… It could be that our GPs say to us, "There is a big
issue around peripheral vascular disease, people aren't
being managed properly." It could be secondary care
clinicians who come to us and say, "There is a new
technology that we think would improve the patient
pathway that we think we should have a look at." It
could come from NHS England or the Health and
Wellbeing Board who see that there is a big issue
around peripheral vascular disease in England …
NICE (National Institute for Health and Care
Excellence) might produce a tag or a guidance around
it. So it could be any of those things … (Senior
Manager, CCG Site 1)
Commissioners suggested that a wide variety of infor-
mation sources are used to inform their prioritisation de-
cisions. This includes intelligence from local public health
teams and comparative benchmarked information from
national data in order to identify unwarranted variation as
a mechanism to releasing resources for re-investment in
higher-value healthcare for local patients and populations.
We use things like the Atlas of Variation, other
benchmarking tools that allow us to see where we are
in relation to other organisations… And on the basis of
that, we develop a set of priorities. We normally set
our priorities three and five years in advance and we
would then look at something, and idea or innovation
that was coming, and then say, "Right, okay. Does that
link with any of our priorities?" If it didn't link with
any of our priorities, we would have a look at it still
Maniatopoulos et al. BMC Health Services Research          (2019) 19:648 Page 4 of 12
and we would say, "Right, okay. Is it something that we
maybe haven't thought of before? Is it something that
we weren't aware of?" (Senior Commissioning
Manager, CCG Site 3)
These comparative measures could operate as forms of
accountability for commissioners by justifying particular
decisions. In so doing, they play a key role in framing future
investment/disinvestment decision-making. Their efforts
involve the construction of a ‘like for like’ comparison be-
tween the health outcomes of local populations.
The very start of the process is we look at health needs
of local population. We look at how we compare and
benchmark to other organisations, and do we have a
particular outcome or adverse outcome either from a
health point of view or from an unmet need point of
view. So we really do look at what the need is of our
local population. How do our patient outcomes
compare to other patient outcomes? (Senior
Commissioning Manager, CCG Site 2)
A number of participants pointed to the benefits of be-
ing able to draw upon the support from national bodies
such as NICE and NHS England, but there was evidence
of a tension between national priorities and the need to
meet the rapidly changing needs of local populations.
Often local conversations could complement national
evidence and information from other localities.
I would be involved in that discussion about whether
something is a priority area for us. If it is a priority
area for us and we agree that we’re going to put it in
as part of our commissioning intentions for next year,
over the course of the year there’ll be development of a
specification for the service, which would include
quality standards, which is my particular part of it.
(Focus Group 2, Clinical Director, CCG Site 4)
The need to respond to priority areas mean that CCGs
are frequently required to make difficult prioritisation
decisions according to the needs of their local populations.
Given the tension between national and local agendas for
some participants competing priorities could hinder
commissioning a pathway for the new diagnostic technol-
ogy in primary care.
I think competing priorities are probably the biggest
[…] and everything’s priority isn’t it? (Senior Manager,
Strategic Clinical Network)
The tensions between national and local agendas and
competing priorities, accompanied by growing financial
pressures on the NHS raised issues and concerns about
the ways in which current commissioning practices
based on measurement of activity - such as waiting times
and the number of patients treated - are organised, man-
aged and performed. Traditionally, most commissioning
processes in healthcare have tended to pay providers for
particular tasks and activities often within a set period of
time, rather than for the delivery of agent’s achievement
of specific results, or outcomes.
It’s very complex; the whole thing is incredibly complex
and you wouldn’t set up commissioning like this if you
were starting from scratch, but we’re working in a
complex environment and we just have to find our
way around it. (Clinical Director/GP, CCG Site 1)
In summary, commissioning decision-making becomes
subject to potentially conflicting criteria under conditions of
uncertainty and competing priorities. By negotiating be-
tween competing agendas, power relationships and personal
choices commissioners strive to build persuasive, compelling
arguments to inform local commissioning decisions.
Valuing evidence
Participants highlighted the role of evidence in commis-
sioning a pathway for the new diagnostic technology. It
was stressed that any commissioning decision should be
informed by a variety of different evidence sources and
expert involvement to ensure that effective decisions are
made for local populations.
The pathways in totality should be evidence-based
pathways. Therefore, anything that’s within that would
need an evidence base to supports its introduction…
Does the introduction of this technology equate to high
quality? Is it safe? Will it actually improve the patient
experience because it’s done closer to home? Does it
join-up with the rest of the system, because there’s no
point introducing a technology in general practice if it
isn’t a technology that’s accepted by secondary care as
part of a process. (Senior Manager, CCG Site 1)
Best practice guidelines and research were described
as potential sources of information commissioners drew
on when making decisions, some of which they sought
out, while others were imposed upon them. Much of the
other evidence that is relevant to commissioning is more
likely to be generated by commissioners themselves (e.g.
assessments of need) and providers of services (e.g. ser-
vice user feedback and outcomes monitoring/evaluation
of outcomes).
All the commissioners in the participating CCGs
stressed that their support for the new diagnostic was on
account of the potential benefits it would have for pa-
tients. Agreeing a shared understanding of the value added
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to the clinical pathway was considered to be important for
developing a business case to support the commissioning
of the new diagnostic technology.
With any new services, whether it is a technology
service or any new pathway, you would be looking
to say, "What is new about this that adds value to
the existing pathway?" Does it improve the quality
of care? Does it improve the patient experience? Is
it more economical? What is the hook? Because
clearly there has got to be a reason why you would
adopt something, so you have to be very clear
about what that reason is… it has got to be two
things. It is a balance between improving the
quality of care but also the efficiency. So is it
value for money? (Senior Manager/GP, CCG Site 2)
In this context, any decision to commissioning the
new diagnostic technology would be subject to commis-
sioners gathering evidence and making a business case:
weighing up cost savings and quality improvements.
Different types of information and analytical resources
were considered to be important in shaping the develop-
ment of a business case for commissioners incorporating
both explicit and tacit knowledge channels. This in-
cluded clinical, ethical, organisational, technological and
economic considerations (e.g. clinical and financial evi-
dence), as well as subjective local judgments (e.g. how
difficult something is) in relation to local implementa-
tion and adoption issues. These factors are not inde-
pendent of each other, and indeed could be mutually
reinforcing and/or conflicting.
Once it fits with that [within priority areas], we
would then have a look at what the innovation is,
have a look at the evidence, see how it links with
any other things that we're doing. What stage is it
at? Is it at trial stage? Has it been used anywhere?
Has it been implemented? And then if we agree
that it's something we want to look at further, we
would then work it up. So it would be worked up
in terms of a business case… We would then
decide, what is the case? Is there a clinical case
there? How strong is the evidence base? What sort
of outcomes will we be looking to achieve? Will it
address the priorities we've identified at the start
of the process? What sort of risks relate to it?
What is the degree of difficulty? What sort of time
frame are we talking? Is it something that could be
implemented quite quickly? Would we recommend
a trial? So, would we be looking at trials, or have
trials already taken place and we would simply be
looking to move to implementation? (Senior
Commissioning Manager, CCG Site 3)
Apart from the importance of structures, resources and
formal processes shaping decision-making, participants
stressed also the importance of ‘soft’ skills of clinical lead-
ership to support innovation and service improvement
through new technologies.
It would need to have been championed clinically
because we are a clinically-led organisation. Before
it gets to the executive, that value would then have
been tested out throughout our financial colleagues
and our performance colleagues and various
interactions throughout the organisation. When it
reaches the executive, it has been sense checked by
a number of different individuals with different
skill sets and different perspectives on a case that
are all then sitting there saying, “The ducks line
up.” (Senior Manager, CCG Site 1)
The implications of these insights for commissioning
decisions for the new diagnostic technology are that im-
portant factors to consider include levels of complexity
and uncertainty, as well as the expected controversy and
impact of decisions. Commissioning decisions take place
in a context characterised by high levels of uncertainty,
where different evidence sources and the decision cri-
teria are negotiable and indeed openly and covertly
contested.
Assessing value for money
Although improvements in patient care were considered
to be important for commissioners, particular emphasis
was also placed to the extent to which implementing the
new diagnostic technology was value for money.
From a CCG perspective… we would look at the cost.
So generally as a rule, as a CCG, things are looked on
better if they are value for money, if they are looking
at releasing resource so we can invest that resource in
to other areas of health care…the clinical side of things
always outweighs the cost side of things. But at the
same time there is a ceiling to what we can pay.
(Senior Commissioning Manager, CCG Site 2)
In this context, the financial evidence would seek to
outline the proposed investment in terms of the afford-
ability of the proposed pathway, the clinical benefits and
the overall value for money. In line with economic argu-
ments associated with new diagnostic technology partici-
pants highlighted the need to demonstrate cost-benefits
across the wider health system.
If there is something that we can demonstrate as either
producing the same outcomes or indeed better
outcomes for less cost or improving outcomes and
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numbers at the same cost then that should be part of
our QIPP [Quality, Innovation, Productivity and
Prevention] plan… (Head of Finance, CCG Site 1)
Participants acknowledged that policy pressures to
deliver short term cost savings meant that long term in-
vestment in patient outcomes was difficult.
So if you can introduce something today that’s going
to make a saving tomorrow, it’s much easier to
account for that […]The hardest thing for a
commissioner to be able to articulate is, “This will
save you lots and lots of money for this particular
individual for this particular cohort of patients in
20 years’ time.” (Senior Manager, CCG Site 1)
The unfortunate thing about the NHS is the
capacity to invest to save five years’ hence is not
there. You need to be able to make savings fairly
quickly… (Focus Group 1, Senior Commissioning
Manager, CCG Site 4)
Moreover, financial pressures and limitations over bud-
gets were considered to be a key barrier for commissioning
a pathway for the new diagnostic technology in primary
care practice making change difficult.
So this very large budget that the commissioners
have, 99% of it is allocated all the time. Because
99% is allocated already, we know it’s going to be
spent on hospitals, community services and social
care, you know, continuing health care. So 1% is
left, it’s quite difficult to commission new stuff with
tiny amounts of money… (Medical Director/GP,
CCG Site 1)
In responding to the above challenges participants dis-
cussed how CCGs are frequently required to strategically
realign resources to enable the commissioning of add-
itional services to both primary and secondary care.
…there is no new money coming in from a CCG. So
you would have to assume that what you want to
commission in addition from general practice will
have a reduction in cost elsewhere…I think that’s
where commissioners have a problem. (Senior
Manager, CCG Site 1)
The need to legitimate value for money accompanied
by growing pressures on service improvement repre-
sented a stark tension between the need for short-term
investment and the longer-term requirement for service
transformation and improvement.
Cross-organisational collaboration
Commissioning of the new diagnostic would only be
possible with re-configurations in clinical workflow and
practices across primary and secondary care. Indeed,
while the implementation of the new diagnostic was
expected to demand reconfigurations across care set-
tings, their exact form and nature was complex and
unclear.
Then what you would have to think about then is,
why is that better than having the diagnostic in
secondary care?… If you wanted to put a service in,
it would depend where you wanted to put it in
primary care. There is tons to unpick there…Do you
want to move the diagnostic into a community
setting or do you want to move it into a General
Practice setting? Who are you expecting to
administer the tool?... There is a limit to the
capacity they have to take on new work. So what
would the workload be if this was coming into
primary care? …but you also have to think about, in
secondary care there will be people that are already
doing diagnostics of some kind for peripheral vascular
disease…Do you re-deploy them?....What do you do?
And actually you need to keep some of it, because of
the people that you are going to look at in primary
care, some of them will need to be referred and need
more sophisticated diagnostics possibly? So there is
something about how do you manage the system to
make sure you don't close something off there that you
are going to need later on. Do you see what I mean?…
No it is not simple at all, not at all (Senior Manager,
CCG Site 1)
Participants acknowledged that closer collaboration be-
tween care settings is key for a potential re-configuration of
a pathway for peripheral arterial disease. In particular,
mutual trust between healthcare professionals in primary
and secondary care was considered to be central to the suc-
cessful implementation of the new diagnostic technology.
The other thing about doing diagnostics in primary
care is that you need specialists to recognise it and
value it. What we can’t afford to do is have diagnostics
that are not supported by specialists because they’ll do
them again … (Senior Manager/GP, CCG Site 2)
Alongside the lack of a clear pathway for the new
diagnostic technology questions were raised about
primary care’s capacity and resources to deliver add-
itional services. While a shorter care pathway and
fewer hospital referrals would be welcome to patients,
there were opportunity costs that might put GPs ac-
ceptability in question.
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Yes, cost; the primary care saying, “Why should we use
this? What is it going to do for us? Is it going to take
more time to do?” Are they going to have longer
appointments? Are their staff going to have to leave
patients to go and get extra training? I think you’d
have to have a big sell to say, “What’s the benefit of
this technology? Why is it good for the patient? Why is
it good for the practice? Why is it good for the CCG?”
(Clinical Director/GP, CCG Site 1)
Lack of time and capacity issues seemed to be appar-
ent within general practice. Participants spoke about
time and capacity limits, as illustrated here:
…General Practice is under a huge amount of
pressure....there is a shortage of GPs. So asking them to
do ever more is sometimes not a question of money, it
is a question of capacity…what incentive is there for
him to take on more work, with no resource, when he
could just refer the patient to the hospital and have it
all done there? (Senior Manager, CCG Site 1)
At the moment, general practice is busy. They
absolutely don’t want any extra work. I just know…
They just don’t have the time to do it... (Senior
Manager/GP, CCG Site 2)
In this context, participants discussed how implement-
ing change in primary care is not always a straightfor-
ward process.
I think it’s probably quite complicated…because each
practice is so different, there are different ways of
working. You might find one practice who are really
outward-looking, really engaged and change, but other
practices won’t have that same attitude. (GP 1)
The complexity of collaborative structures across pri-
mary and secondary care needs to be considered when
exploring the process by which commissioning organisa-
tions make their decisions to commission innovative
health technologies. Although the commissioning of the
new diagnostic promised benefits over existing prac-
tice(s), its adoption also involved reconfigurations across
a multi-level set of work practices that were not always
easy to implement.
Negotiating commissioning pathways
The uncertainty associated with the lack of a clear pathway
for the new diagnostic technology raised also concerns about
the potential commissioning re-configurations required to
implement the new care pathway. Overall, participants talked
about the difficulties in moving resources between different
care settings.
What would you expect to pay GPs to do that bit of the
diagnostic? How would you unbundle that from the
current tariff that we have with secondary care? Because
at the moment the tariff we have for a new outpatient
appointment includes the diagnostics. So you would
have to unbundle that and say, "Okay, if it is £80 for a
new out-patient appointment in second care and that
includes the diagnostic, how much are you
going to take out of that and give it to the doctor in
primary care to do?"… That is going to be your biggest
problem… So there are two issues, one is have they got
the capacity to do it? And the other is can you pay them
to do it? (Senior Manager, CCG Site 1)
Given that a number of diagnostic services are currently
provided in secondary care it was unclear how a potential
re-configuration of commissioning arrangements from
secondary to primary care could be achieved.
It won't be financially sensible for CCGs to do that
because we already pay. Why should we pay more for
a GP to do it again? We already pay the Community
Trust for a service. Why would we pay the GP to do it?
By taking the work out of the Community Trust, it’s
not going to reduce our block contract. It’s exactly the
same value. Why? Why would we pay more? (Senior
Manager/GP, CCG Site 2)
The financial implications of a whole systems approach
across primary and secondary care raised concerns for
some of the participants. In particular, participants revealed
that by moving the diagnostic into primary care with the
potential of reducing unnecessary referrals to secondary
care could result in a loss of income to secondary care.
There will be a huge argument about it, because
primary care want more money, secondary care
don't want to lose it… So they will say, "That £80
that you gave us, only £20 of that is the diagnostic,
the other £60 is administering the appointment,
seeing the patient, the consultant's time, the nurse's
time, the prescription that they might get at the end
of it…But in primary care they will be saying, "Of
that £80, if you want us to do this we want £40 of
it."…And you have got to persuade primary care
that it is in the best interest of patients to do
that… (Senior Manager, CCG Site 1)
So hospitals now are much more likely to obviously
look at the clinical benefits of what it is that they
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do, but also as likely to look at which the financial
consequences are for them of participating in it as
well. Do they lose money?... It always comes back to
the resource. (Senior Commissioning Manager, CCG
Site 2)
Some participants considered the root of this problem
as the ‘silo’ culture, where primary and secondary care
organisations operate as independent units.
There are all sorts of reasons why you would want
to do that but the flow of money is a barrier to
that…because they are two different organisations…
There is no payment by results for primary care. It
does exist in hospital. It doesn’t exist in primary
care. Often that is a huge barrier… (Medical
Director/GP, CCG Site 1)
The money, agreeing what we were going to pay GPs to
do this, instead of the patient going to hospital and
agreeing that. Taking the money out of the hospital
budget. When money is really scarce, as it is now,
nobody gives it up willingly, without a fight. So the
hospital – what was the incentive for them to give up
this activity that generated money for them? (Senior
Commissioning Manager, CCG Site 3)
Given the above challenges some participants argued
that the healthcare economy would benefit from a more
integrated approach in both the commissioning and the
delivery of patient services. In particular, it was sug-
gested that recent initiatives around the development of
new care models could provide solutions to long stand-
ing commissioning barriers between primary and sec-
ondary care by removing organisational boundaries and
redesigning poorly aligned financial incentives across
different stakeholders which have historically prevented
transformation in care [26].
Discussion
Drawing upon Strauss’ negotiated order perspective [9, 10]
this paper has explored the process by which commission-
ing organisations make their decisions to commission a
pathway for the new diagnostic technology in primary care
practice. This approach enables analysis of the negotiations
that occur in commissioning decision making, as well as
consideration of the interdependencies among factors shap-
ing this process. By putting the focus on commissioning,
we want to show how decisions become subject to uncer-
tainty driven by the micro-politics of the organisational
setting, competing agendas, interests, priorities, demands
and personal inclinations to build a persuasive, compelling
case. Instead of adopting a simple technical rationality, our
study aims to understand how decision-making becomes
enacted in the context of healthcare commissioning by ex-
ploring the social structures and conditions that shape
those processes.
We explored these issues through a case study linked
to the commissioning of a new type of diagnostic tech-
nology for peripheral arterial disease in primary care,
which illustrated some of the challenges surrounding
commissioning a pathway for its embedding into health-
care practice. Although the implementation of the new
diagnostic promises wide-ranging benefits over existing
practice(s) such as the opportunity to improve diagnostic
accuracy and to identify patients that need either re-
assurance, primary prevention of cardiovascular risk fac-
tors or onward referral for specialist intervention, we
saw how its commissioning involved high levels of pro-
tracted negotiations over funding, managing competing
priorities, alliance building, conflict resolution and re-
quired reconfigurations across a multi-level set of work
practices that were not always easy to implement [27].
Our evidence highlighted the important role of priority
setting in commissioning a pathway for the new diagnostic
technology in primary care practice [28]. However, resource
limitations, competing priorities and a lack of a clear path-
way could be the key challenges in the commissioning the
new diagnostic technology in the NHS. Currently, there is a
high degree of variation related to the availability and deliv-
ery of PAD services across primary and secondary care. In
many instances PAD services are only commissioned at the
end of the patient journey in the hospital setting where diag-
nosis and intervention (or not) usually happens. Currently,
there is little evidence for formally commissioning a PAD
pathway and the management of such patients appear to
happen by default. This may be linked to healthcare spend-
ing priorities or to an assumption that cardiovascular risk
factors associated with PAD are managed in other commis-
sioned parts of the health system and hence only addressing
the end-stage of the patient journey by commissioning hos-
pital-based intervention services.
Further and wider evidence will always be required to
assess the potential patient benefits, clinical value and
cost savings for commissioning a pathway for a new
diagnostic technology. Our findings suggest that most
commissioners will look towards NICE (National Institute
for Health and Care Excellence) and/or local clinical
networks and clinical champions for guidance on commis-
sioning decisions, particularly where the evidence is lack-
ing [29]. It is incumbent upon these individuals and
organisations to make the business case, articulate the
patient benefits and demonstrate value for money that the
NHS receives for its investment or realignment of services
and spend. However, of particular concern among the
participants was that too much was being expected too
soon in terms of demonstrating a ‘return on investment’
in innovative health technology investments.
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At the clinical pathway level, our data, suggests that
whilst clinical champions can be important facilitators for
commissioning a pathway for the new diagnostic technol-
ogy, reconfigurations of work practices within and across
care settings and professional groups [29, 30] to support
the implementation of the new technology requires much
more and remains unclear. In particular, closer cross-or-
ganisational collaboration and trust between healthcare
professionals in primary and secondary care was considered
to be central to reconfiguring the care pathway [31, 32].
Alongside the need for reconfigurations of work practices
within and across care settings questions were raised about
primary care’s capacity and resources to deliver additional
services as ABPI assessment is primarily performed by sec-
ondary care commissioned community staff [33]. While a
shorter care pathway and fewer hospital referrals would be
welcome to patients, there were implications that might
put GPs acceptability in question. Ultimately, failure to
deploy accurate diagnostic technology in a primary care
setting could result in unnecessary referrals of individuals
without PAD or delay in access to specialist services for
those that require intervention and thus more costs and
poorer patient outcomes.
At an organisational level, commissioning a pathway for
the new diagnostic technology in the NHS required
addressing uncertainty about the effectiveness of a proven
business model. From a commissioning perspective, mak-
ing a case for the implementation of the new diagnostic
demanded significant inter-organisational work if com-
missioners were to be convinced that this could be done
within acceptable levels of risk financially and operation-
ally [34]. This required removing the artificial barriers
between primary and secondary care commissioning
which could lead to disjointed services with variable access
to diagnostic services in pathways [35]. Some of the artifi-
cial barriers articulated in this work have been quite stark.
From the primary care perspective clinicians are incenti-
vised to reduce demands upon the healthcare system and
to minimise referrals. Conversely, primary care doctors
often don’t have time to perform a diagnostic work-up of
patients which leads to an automatic default of onward
referral to specialist services. On the whole the diagnostic
work-up in terms of ABPI assessment is performed by
secondary care commissioned community staff. Currently
there is a perverse incentive to allow all patients to pro-
gress to referral which will attract Payment by Results
(PbR) tariff - the system in NHS England under which
commissioners pay healthcare providers for each patient
treated, taking into account the complexity of the patient’s
healthcare needs [36] - income to the secondary care pro-
vider of those services.
In summary, this study reveals that the commission-
ing of innovative health technologies, such as a new
diagnostic technology for PAD, is currently ‘messy
and fragmented’ [37]. It involves high levels of pro-
tracted negotiations over funding between providers and
commissioners, alliance building, conflict resolution and
compromise of objectives where the outcomes of change
are highly contingent upon interventions made across
different care settings. Our evidence illustrates how recon-
figurations of inter-organisational relations, and of clinical
and related work practices required for the successful
implementation of a new technology could become a
major stumbling block to commissioning negotiations. In
so doing, we aim to contribute to the growing area of
health services commissioning by providing a more com-
prehensive analysis of the decision making processes
surrounding the commissioning of new technologies.
Learning more about how commissioners in the real
world make their decisions to commission innovative
health technologies is important in order to increase our
understanding about the contribution that researchers
and research evidence can make to policy-making.
In the light of the new care models programme across
the UK [26, 38] there is now a window of opportunity to
examine and evaluate the impact of Integrated Care
Systems (ICSs) for the adoption of new innovative health
technologies such as the diagnostic technology for PAD.
This could facilitate the development of effective prac-
tical and feasible solutions for the commissioning and
provision of new care pathways.
Limitations
This study is based upon the experience of senior clini-
cians in commission roles and commissioning managers
in a number of Clinical Commissioning Groups in one
geographical region in England and may not be sensitive
to the subtle variations across the UK. We also acknow-
ledge that a potential limitation of our analysis is the focus
on commissioning a single technological innovation as an
example, which raises questions about the extent to which
the commissioning tensions identified are common to
other technological innovations in healthcare - there is
certainly scope for future wider research to address these
matters. Because the focus is solely on NHS commission-
ing the role of private health care providers of diagnostics,
such as pharmacy outlets, needs also to be considered.
Conclusion
Innovative health technologies such as new diagnostic tech-
nology for PAD are commissioned in care pathways where
the value of such technology is realised by those delivering
care to patients. The detail of how care pathways are
commissioned is complex and involves high degrees of
uncertainty concerning such issues as prioritisation deci-
sions, patient benefits, clinical buy-in, value for money and
unintended consequences. The likely successful commis-
sioning and implementation of such technology in the NHS
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will depend on reconfigurations across a multilevel set of
practices and its impact on patient outcomes associated
with care pathways. Recent developments in the new care
models and integrated care systems (ICSs), which aim to
remove cross-organisational barriers/tensions in the UK
offer a unique opportunity for the successful commission-
ing arrangements of innovative health technologies in
primary care such as the new diagnostic technology for
peripheral arterial disease.
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